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Background: While it is now more than a decade since the first description of the gene mutation underlying the
tumour predisposition syndrome multiple endocrine neoplasia type 1 (MEN1), the mechanism by which its protein
product menin acts to prevent development of tumours is still poorly understood.
Methods: We undertook a genetic experiment to assess whether menin synergises with p53. Mice carrying various
combinations of Men1 and Trp53 mutations were generated then survival and pathology assessed.
Results: While homozygous loss of Trp53 in mice resulted in early onset, aggressive tumours and profoundly
reduced lifespan, heterozygous loss of either Trp53 or Men1 caused later onset disease, with a spectrum of tumours
characteristic of each tumour suppressor gene. Loss of one copy of Men1 in animals also lacking both alleles of
Trp53 did not exacerbate phenotype, based on survival, animal weight or sites of pathology, compared to Trp53
deletion alone. Dual heterozygous deletion of Men1 and Trp53 resulted in a small reduction in lifespan compared to
the individual mutations, without new tumour sites. In the adrenal, we observed development of cortical tumours
in dual heterozygous animals, as we have previously seen in Men1+/− animals, and there was loss of heterozygosity
at the Men1 allele in these tumours. Median number of pathology observations per animal was increased in dual
heterozygous animals compared with heterozygous loss of Trp53 alone.
Conclusions: Simultaneous heterozygous deletion of Men1 in animals with either heterozygous or homozygous
deletion of Trp53 did not result in formation of tumours at any new sites, implying additive rather than synergistic
effects of these pathways. Mice that were Men1+/− in addition to Trp53+/− had tumours in endocrine as well as
other sites, implying that increase in total tumour burden, at sites typically associated with either Men1 or Trp53
loss, contributed to the slight decrease in survival in Men1+/−: Trp53+/− animals in comparison with their littermates.Background
Menin, the tumour suppressor product of the MEN1
gene that is mutated in the human tumour predisposition
syndrome multiple endocrine neoplasia type 1 (MEN1),
is a 610 amino acid protein with no homology to any
known proteins [1,2]. Menin localises predominantly to
the nucleus, and is associated with a variety of proteins
that implicate it in signal transduction pathways, as a
transcriptional co-regulator, and in regulation of chro-
matin [3-5]. One of the proteins that associates with
menin is the Fanconi anaemia protein FANCD2 [6],
which is involved in response to DNA damage and* Correspondence: kelly.loffler@qimr.edu.au
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reproduction in any medium, provided the orparticipates in the BRCA/p53 pathway of tumour sup-
pression [7].
Both spontaneous and familial cases of human MEN1
mutation result in predisposition to a range of tumour
types, predominantly in endocrine organs such as para-
thyroid, pituitary and enteropancreatic sites [8]. Several
groups have published mouse models of MEN1, which
replicate the human syndrome and result in tumour de-
velopment, most commonly in endocrine pancreas, pitu-
itary, parathyroid and thyroid glands, adrenals, in the
gonads in some models, as well as other rarer sites [9-12].
Mutation of the TRP53 gene encoding p53 has been
associated with many tumour types [for recent review of
p53 biology see 13]. Sporadic somatic mutations are
commonly detected in different cancer types, and occur
along the length of the gene. Hereditary TRP53 muta-
tions are associated with Li Fraumeni syndrome (LFS),Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Survival analysis of animals by genotype. Animals were
culled on noting morbidity or distress, or at 21 months of age, and
full necropsies carried out. Presence of any kind of overt gross
pathology, including tumours or other abnormalities, was scored as
an event. Data is plotted as a cumulative surviving percentage of
the cohort of animals, versus age in months.
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early onset tumour development, multiple tumours within
an individual, and multiple affected family members.
The most frequent tumour types in LFS are soft tissue
sarcomas and osteosarcomas, breast cancer, brain tu-
mours, leukaemia, and adrenocortical carcinoma (OMIM
151623). Mouse models of Trp53 deletion also exhibit a
range of cancer types, particularly sarcoma and lymph-
oma [14,15].
Our previous experiments have indicated that com-
pound heterozygous loss of both Men1 and Rb1 genes
has little effect on the rate, severity or onset of tumori-
genesis, or on the spectrum of observed tumour types
compared to individual gene deletions [16]. In contrast,
the comparable cross of animals with heterozygous loss
of both Rb1 and Trp53 genes resulted in a marked in-
crease in severity, decreased median lifespan, and the oc-
currence of novel tumour types not observed in either of
the individual knockout animals [17,18]. Trp53 can act
synergistically with Brca2 [19] and Cdkn2c [20], a known
menin-regulated gene [5,21]. p18, the protein product of
Cdkn2c, also collaborates with menin to suppress neu-
roendocrine tumorigenesis [22]. We therefore sought to
ascertain whether a similar genetic interaction would be
observed between Men1 and Trp53.
Methods
Mice with a targeted disruption of exon 2 of Men1 have
been previously described, and were genotyped by PCR
from tail or ear biopsy DNA [11]. Mice with targeted de-
letion of Trp53 obtained from Tyler Jacks were main-
tained and genotyped as previously described [15]. A
cohort of animals including various combinations of the
two tumour suppressor gene deletions were generated
by cross-breeding and maintained under authorisation
from the Queensland Institute of Medical Research Ani-
mal Ethics Committee in compliance with the Australian
Code of Practice for the Care and Use of Animals for
Scientific Purposes, in standard housing conditions with
12 hour light–dark cycle with food and water available
ad libitum. Animals of the expected range of genotypes
were born and viable, and all initially appeared normal
and healthy. Cohorts were subsequently monitored pe-
riodically for signs of illness or overt tumour devel-
opment. Upon observation of morbidity, animals were
euthanased by CO2 asphyxiation, weighed, and a full
necropsy carried out. At 21 months the experiment was
terminated and all remaining animals culled and ne-
cropsies performed. At necropsy any pathology such as
tumours or other grossly visible abnormalities were noted.
Tissues were rinsed in PBS then fixed overnight in 10%
neutral buffered formalin, washed in 70% ethanol and
re-assessed using a stereomicroscope to confirm obser-
vations. Age was calculated using the date of birth anddate of death to calculate the age in days, then divid-
ing this value by 30.416667 to approximate the age in
months. Survival was plotted in GraphPad Prism 5.01
for Windows, and Kaplan-Meier survival curves were
analysed using Gehan-Breslow-Wilcoxon tests (GraphPad
Software, San Diego U.S.A.). P values less than 0.05 were
considered significant. Whole animal weights in grams
were compared by one way ANOVA with Tukey’s cor-
rection for multiple comparisons. Pathology data from
necropsy observations was tabulated by genotype group
then analysed using PASW Statistics 17.0 (SPSS Inc.,
Chicago U.S.A.). Loss of heterozygosity was assessed by
isolation of genomic DNA from formalin fixed tissues,
followed by genotyping PCR as previously described [16].
Products were separated by agarose gel electrophoresis,
photographed and band intensities calculated using
ImageJ image analysis software (NIH). Paraffin embed-
ding and hematoxylin and eosin staining of tissues was
carried out by the University of Queensland-Queensland
Institute of Medical Research Histotechnology Facility,
and sections were scanned using an Aperio Scanscope
XT (Aperio Technologies, Vista U.S.A.). Histopatholo-
gical assessment of adrenal sections was carried out a
histopathologist (PMW), who was blinded to the geno-
types of the animals.
Results
Survival analyses
Survival analysis indicated that homozygous deletion of
Trp53 resulted in dramatically shortened lifespan com-
pared to wild-type mice, however the further loss of
one allele of Men1 had no significant modifying effect on
median survival (Men1+/+: Trp53−/− median 5.29 months,
mean 5.192 months, SD 1.172; Men1+/−: Trp53−/− median
4.85 months, mean 5.016 months, SD 1.287) (Figure 1).
Mice with heterozygous deletion of either Men1 or Trp53
had decreased survival compared to their wild-type litter-
mates. Combined heterozygous deletion of both Men1
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lifespan of almost two months compared to either of
the individual mutants (Men1+/−: Trp53+/+ median
14.47 months, mean 15.76 months, SD 4.061; Men1+/+:
Trp53+/− median 14.70 months, mean 15.10 months, SD
1.804; Men1+/−: Trp53+/− median 12.79 months, mean
12.22 months, SD 3.479; p< 0.02). Most of the Men1+/+:
Trp53+/+ animals survived in apparent health until
21 months old, at which time all remaining animals were
culled and the experiment ended (median age 21.14 months,
mean 19.10 months, SD 3.756).
Gross pathology observations
As was expected based on our previous analyses of mice
lacking one copy of Men1, the main pathologies ob-
served in the Men1+/−: Trp53+/+ cohort were in the pan-
creas, pituitary, gonads, and adrenal glands (Table 1).
Gross pathologies observed in our cohort of Men1+/+:
Trp53+/− and Men1+/+: Trp53−/− animals were consistent
with published descriptions of other Trp53 knockouts,
most commonly including lymph node and spleen path-
ologies, consistent with the frequent lymphoma ob-
served previously by others. Men1+/−: Trp53−/− animals
showed essentially the same range of gross pathology
that was observed in Men1+/+: Trp53−/− animals. Men1+/−:
Trp53+/− animals presented with a range of gross path-
ologies consistent with the phenotypes observed in theTable 1 Pathology observed grossly, by anatomical site
Men1+/+; Trp53+/+ Men1+/+; Trp53+/− Men1+/+;
Pituitary 4/13 (30.8%) 0/9 0 1/13
Pancreas 0/13 0 1/9 (11.1%) 1/13
Thyroid 3/11 (27.3%) 0/8 0 0/11
Parathyroid 1/11 (9.1%) 1/8 (12.5%) 0/11
Thymus 0/13 0 0/9 0 3/13
Lymph Nodes 2/13 (15.3%) 3/9 (33.3%) 9/13
Spleen 1/13 (7.7%) 1/9 (11.1%) 7/13
Muscle 0/13 0 1/9 (11.1%) 5/13
Bone 0/13 0 3/9 (33.3%) 0/13
Bladder/Urethra 0/13 0 2/9 (22.2%) 0/13
Prostate/Seminal Vesicles 2/5 (40.0%) 2/6 (33.3%) 1/5
Testes 0/5 0 1/6 (16.7%) 1/5
Uterus 3/8 (37.5%) 2/3 (66.7%) 0/8
Ovaries 0/8 0 1/3 (33.3%) 1/8
Mammary Glands 1P/13 (7.7%) 0/9 0 0/6
Adrenal Glands 0/13 0 1/8 (12.5%) 3/13
Lung 3/13 (23.1%) 1/9 (11.1%) 3/13
Liver 1/13 (7.7%) 3/9 (33.3%) 3/13
Data are shown as "Number of animals with abnormal or pathology observation"/"T
For mammary observations, L indicates appearance similar to lactation as seen duri
animals with pituitary prolactinoma, P indicates other pathology.individual mutants. No tumours were observed in or-
gans that were not affected in either of the single mu-
tants. Comparisons for each organ or site of pathology
between genotype groups (Table 1) indicated that there
were no statistically significant differences between Men1+/−:
Trp53−/− and Men1+/+: Trp53−/− animals in tumorigenesis
rates at any site. There were also no significant differ-
ences between Men1+/−: Trp53+/+ and Men1+/−: Trp53+/−
cohorts at any site. In a few organs there were however
differences between Men1+/+: Trp53+/− and Men1+/−:
Trp53+/− cohorts (Two sided Fisher’s Exact Tests: pituit-
ary p = 0.011, pancreas p = 0.045, uterus p = 0.038, other
sites not significant).
Pancreatic pathology observations
As has been previously observed, pancreatic endocrine
pathology is frequently observed in Men1+/− animals [9-12],
and in our Men1+/− animals was histologically described
as adenoma, which were typically immunopositive for
insulin [11]. Gross pathology was observed at similar
rates in the Men1+/−: Trp53+/+ and Men1+/−: Trp53+/−
cohorts here, as discussed above. Histologically, the ap-
pearance of islet tumours in Men1+/−: Trp53+/− animals
was not distinguishable from that we have observed in
the Men1+/−: Trp53+/+ animals at a comparable age. For
example, Figure 2 shows haematoxylin and eosin stained
sections from the pancreas of Men1+/−: Trp53+/+ andTrp53−/− Men1+/−; Trp53+/+ Men1+/−; Trp53+/− Men1+/−; Trp53−/−
(7.7%) 14/19 (73.7%) 11/21 (52.4%) 5/28 (17.9%)
(7.7%) 13/19 (68.4%) 12/22 (54.5%) 4/28 (14.3%)
0 5/17 (29.4%) 9/22 (40.9%) 4/27 (14.8%)
0 4/17 (23.5%) 5/22 (22.7%) 0/27 0
(23.1%) 1/19 (5.9%) 2/22 (9.1%) 11/28 (39.3%)
(69.2%) 4/19 (21.1%) 9/22 (40.1%) 20/28 (71.4%)
(53.8%) 3/19 (15.8%) 4/22 (18.2%) 21/28 (75.0%)
(38.5%) 1/19 (5.3%) 3/22 (13.6%) 6/28 (21.4%)
0 3/19 (15.8%) 2/22 (9.1%) 1/28 (3.6%)
0 0/19 0 0/22 0 1/27 (3.7%)
(20.0%) 1/9 (11.1%) 4/12 (33.3%) 1/15 (6.7%)
(20.0%) 5/9 (55.6%) 7/12 (58.3%) 2/16 (12.5%)
0 2/10 (20.0%) 0/10 0 0/11 0
(12.5%) 5/10 (50.0%) 6/10 (60.0%) 5/11 (45.5%)
0 1 L/18 (5.6%) 1 L,1P/17 (5.9%L,5.9%P) 0/14 0
(23.1%) 5/18 (27.8%) 9/21 (42.6%) 6/28 (21.4%)
(23.1%) 2/19 (10.5%) 4/21 (19.0%) 3/28 (10.7%)
(23.1%) 1/19 (5.3%) 2/21 (9.5%) 6/28 (21.4%)
otal number of animals" (percentage of cohort), tabulated by genotype group.
ng normal pregnancy or suckling, as we have previously observed in some
Men1+/-: Trp53+/+ Men1+/-: Trp53+/-
Figure 2 Pancreatic pathology. Haematoxylin and eosin stained sections from the pancreata of littermate Men1+/−: Trp53+/+ and Men1+/−:
Trp53+/− animals as indicated (both between 12 and 13 months old at time of necropsy). Bars represent 500 μm.
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large, highly vascular adenomas, but notably some small-
er and histologically normal islets are still apparent in
each of these animals. Consistent with the younger age
at necropsy in Men1+/−: Trp53−/− animals, islets in these
animals were sometimes hyperplastic but had rarely pro-
gressed to frank adenoma (not shown).
Adrenal pathology observations
Adrenal pathology is sometimes observed in Men1+/−
animals [9-12], and was apparent at a statistically similar
rate in our Men1+/−: Trp53+/− cohort. We obtained gen-
omic DNA from some of these adrenal tumours, and by
comparison with normal tissue (from the liver of the
same animal), observed that these adrenal tumours had
undergone loss of heterozygosity at the Men1 locus, with
relative over-representation of the deleted allele (Figure 3
A and B).
Histological analysis revealed that large adrenal tu-
mours in several Men1+/−: Trp53+/− animals were cor-
tical adenomas or carcinomas, similar to those we had
previously observed in our analysis of Men1+/− animals
[11]. Figure 3C shows adrenal histology from litter mate
Men1+/−: Trp53+/+ and Men1+/−: Trp53+/− animals (14
and 12 months old respectively), in which both animals
developed similar cortical adenoma and hyperplasia. In
two Men1+/−: Trp53−/− animals in which pathology was
grossly observed in the adrenal, histological assessment
showed one of these to be a teratocarcinoma, and an-
other was a poorly differentiated malignant neoplasm of
uncertain origin, most likely an undifferentiated cortical
carcinoma.
Animal weight
We also compared weight between genotype groups
(Figure 4). The Men1+/+: Trp53−/− (mean 34.36 g, range
21.7 – 52.5) and Men1+/−: Trp53−/− (mean 31.98 g, range
15.1 – 44.4) animals, while not significantly different
from each other, were generally lighter than the other
genotype cohorts. There were no significant differencesin weight between Men1+/−: Trp53+/+ (mean 44.49 g,
range 25.9 – 59.0), Men1+/+: Trp53+/− (mean 44.44 g,
range 28.3 – 54.1), Men1+/−: Trp53+/− (mean 45.07 g, range
27.0 – 61.5) and Men1+/+: Trp53+/+ (mean 45.68 g, range
37.3 – 53.4) cohorts, indicating that general growth and
development of these animals was not grossly disrupted.
Occurrence of multiple pathology observations
A defining feature of both MEN1 and Li Fraumeni syn-
dromes is the occurrence of multiple tumours, and a
possible explanation for the decreased lifespan of the
dual heterozygous animals compared to either of the in-
dividual lines may be increased overall tumour burden.
This could be indicated by a higher total number of
pathology observations per animal. As shown in Figure 5,
pathology observations were recorded in multiple organs
for most animals in all cohorts, including some of the
wild-type littermates (Men1+/+: Trp53+/+), which gener-
ally reached very advanced age but nevertheless had of-
ten developed several minor pathologies. Comparison of
the number of scored “pathological” observations per
animal indicated that Men1+/−: Trp53+/− animals pre-
sented with a median of four pathological events com-
pared to two for Men1+/+: Trp53+/− animals (p = 0.016,
Fisher’s Exact Test) or three in the Men1+/−: Trp53+/+
cohort (p=0.715, Fisher’s Exact Test). Men1+/−: Trp53−/−
animals showed a median of three observed pathologies
while Men1+/+: Trp53−/− animals showed two (p = 0.183,
Fisher’s Exact Test).
Discussion
Homozygous deletion of the mouse Men1 gene is lethal
during embryogenesis [9,23], while homozygous deletion
of Trp53 in mice results in rapid onset development of
multiple tumours and severely shortened lifespan com-
pared to wild-type animals, or even to animals with
heterozygous deletion of Trp53 [14,15]. Compound het-
erozygous Men1+/−: Trp53+/− animals described here
were viable into adulthood, and median survival was
much longer than the corresponding cohort of animals
Figure 4 Animal weight at necropsy by genotype. Mean whole
animal weight at necropsy (grams), by genotype group. Error bars
























Animal 1 Animal 2
Figure 3 Adrenal pathology. PCR was used to assess the
representation of wild type and mutated alleles of Men1 in genomic
DNA from adrenal tumours, and from liver from the same animal as
a control (A). Results of these assays were quantified and the relative
representation of the mutated compared to the wild type allele in
tumours was normalised to the band intensities in the liver of the
same animal. Mean (+SE) of triplicate experiments is shown in (B).
(C) Histopathology of adrenal glands from litter mate Men1+/−:
Trp53+/+ and Men1+/−: Trp53+/− animals (14 and 12 months old
respectively at necropsy) as indicated, showing similar cortical
hyperplasia and adenoma development. Bars represent 500 μm.
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one copy each of both Men1 and Trp53 is not biologically
equivalent to losing both copies of Trp53 or of Men1.
Animals with homozygous deletion of Trp53, particu-
larly those which also had deletion of one copy of Men1,
had lower whole body weights at necropsy, which we at-
tribute primarily to the much younger age at which
these animals showed onset of disease symptoms. A sec-
ondary contributing factor may be that when the Men1+/+:
Trp53−/− and Men1+/−: Trp53−/− animals became ill they
appeared to lose condition rapidly, and thus by the time
of necropsy may have lost weight compared to remain-
ing animals that were still healthy at the same age. This
may be comparable to the wasting or cachexia often
observed in human cancer patients.We monitored the occurrence of tumours in these
cohorts of animals and found that an endocrine pattern
of tumorigenesis similar to that seen in MEN1 syndrome
in humans, and in mice with heterozygous deletion of
Men1, is still apparent when combined with heterozy-
gous loss of p53. The tumour types associated with LFS
in humans with heterozygous loss of TRP53 are not per-
fectly recapitulated by heterozygous or homozygous loss
of Trp53 in mice, however each of these is associated
with its own particular spectrum of tumour development
[14,15]. We have noted that each of these spectra is also
retained in combination with Men1+/−. We thus con-
clude that mutations affecting either p53 or menin are
associated with particular cellular consequences which
correspond to propensity for tumorigenesis in particular
tissues, and that additional mutations affecting the other
pathway have negligible effect in terms of tissue specifi-
city of tumour development. The absence of additional
tumour sites is in contrast to previous descriptions of
genetic interaction between Trp53 and Rb1 in which tu-
mours develop in additional sites as well as with in-
creased severity, resulting in dramatically shortened
lifespan [17,18].
Notably, the sites where pathology frequencies varied
between Men1+/+: Trp53+/− and Men1+/−: Trp53+/− co-
horts included the pancreas and pituitary, which are typ-
ical sites of Men1-associated tumorigenesis in mice, and
the uterus, which may be affected by alterations in hor-
mones secondary to pituitary pathology.
Conclusions
Both Li-Fraumeni and MEN1 syndromes are associated
with high risk of development of multiple tumours
(OMIM 151623 and 131100). This is also the case in
both Men1+/− and Trp53+/− mice, as we and others have
Figure 5 Number of pathology observations per animal by genotype. Data from observations at necropsy were recorded and the total
number of pathological/abnormal observations per animal compiled. Data are plotted by genotype as indicated, with each individual animal
represented as a dot point, and median number of observations per animal for each genotype group indicated by a horizontal line. * p< 0.05,
**p< 0.01, ***p< 0.001, Fisher’s exact test.
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tion of highest median number of pathology observations
per animal in the Men1+/−: Trp53+/− cohort indicates
that tumours at more sites, likely corresponding to in-
creased total tumour burden, was the cause underlying
the steeper slope of the survival curve for these animals
in comparison with either mutation alone. This resulted
in the shortening of median lifespan for the Men1+/−:
Trp53+/− cohort.
Mice with a combination of mutations affecting p53
and menin retain both of the tissue specific patterns of
tumorigenesis associated with each of these tumour sup-
pressors. They develop cancers in the endocrine pattern
typically associated with MEN1 [8-12] and the sarcoma/
lymphoma constellation that has been typically linked to
the p53 pathway [14,15]. These data imply that menin
and p53 have independent and non-synergistic effects
on tumorigenesis.
We cannot exclude the possibility that these mutations
have consequences that result in changes in biology at a
molecular level in individual cells, however this is not
apparent at the level of gross tumour development. This
implies some level of plasticity or compensation, or of
independent pathways of activity for menin and p53.
We postulate that the increased total tumour burden,
without new tumour types, in the compound Men1+/−:
Trp53+/− cohort underlies the slightly shorter median
survival of the compound heterozygous animals, com-
pared to heterozygous loss of either of these tumour
suppressor genes alone.TRP53 is very frequently mutated in many types of
tumours, however comprehensive sequencing of exomes
of sporadic human pancreatic neurendocrine tumours
identified mutations in Trp53 in only two of 68 tumours
[24]. The molecular pathway by which p53 acts to pre-
vent tumour development can be disrupted in cancers
by multiple mechanisms, not only by sequence mutation
of the gene itself [for example 25] but the experiment
described here provides genetic confirmation that dis-
ruption of the broader p53 pathway is unlikely to be im-
portant in these endocrine tumour types. Therapeutic
avenues targeting the p53 pathway are therefore likely to
be of little clinical utility in treatment of such tumours.
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